Webinar

Oncology Value Coalition: Bringing Precision Medicine Solutions to the Cancer Journey, Part 4

In part 4 of the Oncology Value Coalition webinar, experts from City of Hope and Highmark discussed how the therapeutic pipeline has changed.

While genomic testing has changed the face of cancer care and ensure more informed decision making, designing precision medicine solutions cannot happen if patients lack access to testing, or if tests results are used incorrectly.

In the latest webinar from The American Journal of Managed Care®'s (AJMC®) Oncology Value Coalition, experts from City of Hope and Highmark highlighted the potential of genomic testing, the opportunities that exist through collaboration between academic centers and the private sector, and the barriers that some patients still face.

Joseph Alvarnas, MD, of City of Hope and editor-in-chief of AJMC®'s Evidence-Based Oncology™, moderated a discussion with:

  • Afsaneh Barzi, MD, PhD, medical director, GI oncology, AccessHope; director, employer strategy, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope
  • Sameera Rahman, MD, senior medical director, Highmark Inc
  • Howard (Jack) West, MD, executive medical director, AccessHope; associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope

In segment 4, panelists discuss how the therapeutic pipeline has changed.

Watch Segment 1

Watch Segment 2

Watch Segment 3

Watch Segment 5

Watch Segment 6

Watch Segment 7

Related Videos
Mei Wei, MD.
Neil Goldfarb, GPBCH
Sandra Cueller, PharmD
Ticiana Leal, MD
Mabel Mardones, MD.
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Dr Bonnie Qin
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo